BIOMAT Database Logo BIOMAT Database Logo

[Pharmacokinetics and biological availability of drug forms of mexiletine in dogs]. 1986

Z Mahrla, and B Augustiniová, and I Sidlíková, and D Lupták, and V Ostrovská, and D Kovácová, and X Svobodová, and P Baricic, and M Durisová

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007267 Injections Introduction of substances into the body using a needle and syringe. Injectables,Injectable,Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008801 Mexiletine Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties. KO-1173,KO1173,KOE-1173,Mexiletene,Mexiletine Hydrochloride,Mexitil,Mexitil PL,Mexityl,Novo-Mexiletine,KO 1173,KOE 1173,KOE1173,Novo Mexiletine
D011437 Propylamines Derivatives of propylamine (the structural formula NH2CH2CH2CH3).
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

Z Mahrla, and B Augustiniová, and I Sidlíková, and D Lupták, and V Ostrovská, and D Kovácová, and X Svobodová, and P Baricic, and M Durisová
[Comparative evaluation of biological availability and anti-arrhythmia effectiveness of Mexicard (mexiletine Polfa)].
January 1989, Kardiologia polska,
Z Mahrla, and B Augustiniová, and I Sidlíková, and D Lupták, and V Ostrovská, and D Kovácová, and X Svobodová, and P Baricic, and M Durisová
Variable pharmacokinetics of mexiletine.
January 1977, Postgraduate medical journal,
Z Mahrla, and B Augustiniová, and I Sidlíková, and D Lupták, and V Ostrovská, and D Kovácová, and X Svobodová, and P Baricic, and M Durisová
Clinical pharmacokinetics of mexiletine.
November 1999, Clinical pharmacokinetics,
Z Mahrla, and B Augustiniová, and I Sidlíková, and D Lupták, and V Ostrovská, and D Kovácová, and X Svobodová, and P Baricic, and M Durisová
[Pharmacokinetics, drug availability and clinical pharmacology of bromhexine].
September 1973, Wiener klinische Wochenschrift,
Z Mahrla, and B Augustiniová, and I Sidlíková, and D Lupták, and V Ostrovská, and D Kovácová, and X Svobodová, and P Baricic, and M Durisová
[Pharmacokinetics, drug availability and clinical pharmacology of bromhexine].
September 1973, Wiener medizinische Wochenschrift (1946),
Z Mahrla, and B Augustiniová, and I Sidlíková, and D Lupták, and V Ostrovská, and D Kovácová, and X Svobodová, and P Baricic, and M Durisová
Pharmacology, electrophysiology, and pharmacokinetics of mexiletine.
May 1984, American heart journal,
Z Mahrla, and B Augustiniová, and I Sidlíková, and D Lupták, and V Ostrovská, and D Kovácová, and X Svobodová, and P Baricic, and M Durisová
Pharmacokinetics of mexiletine in renal insufficiency.
September 1982, British journal of clinical pharmacology,
Z Mahrla, and B Augustiniová, and I Sidlíková, and D Lupták, and V Ostrovská, and D Kovácová, and X Svobodová, and P Baricic, and M Durisová
Pharmacokinetics of mexiletine in the elderly.
April 1989, Journal of clinical pharmacology,
Z Mahrla, and B Augustiniová, and I Sidlíková, and D Lupták, and V Ostrovská, and D Kovácová, and X Svobodová, and P Baricic, and M Durisová
Pharmacokinetics of mexiletine in renal insufficiency.
January 1980, Acta cardiologica. Supplementum,
Z Mahrla, and B Augustiniová, and I Sidlíková, and D Lupták, and V Ostrovská, and D Kovácová, and X Svobodová, and P Baricic, and M Durisová
[Biological availability and pharmacological effects of Prazosin VUFB in dogs].
July 1984, Ceskoslovenska farmacie,
Copied contents to your clipboard!